(A) Overall and (B) progression-free survival stratified by disease transformation. (C) Relapse rate stratified by disease transformation. (D) Overall and progression-free survival in patients with indolent disease and related grafts (n = 26). Seattle non-Myeloablative Conditioning.
 Reprinted with permission from Rezvani et al.¹⁸